Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (GFM-AZA-VOR)
This study is not yet open for participant recruitment.
Verified December 2012 by Groupe Francophone des Myelodysplasies
Sponsor:
Groupe Francophone des Myelodysplasies
Collaborator:
Merck
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies
ClinicalTrials.gov Identifier:
NCT01748240
First received: December 7, 2012
Last updated: December 10, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is not yet open for participant recruitment. |
|---|---|
| Estimated Study Completion Date: | March 2016 |
| Estimated Primary Completion Date: | March 2015 (Final data collection date for primary outcome measure) |